J&J Agrees to $5.5 Billion Settlement to End Decade of Talc Cancer Lawsuits
Johnson & Johnson agrees to pay $5.5 billion to settle ~76,000 lawsuits claiming its talc baby powder caused ovarian cancer, ending 10+ years of litigation.
Johnson & Johnson agrees to pay $5.5 billion to settle ~76,000 lawsuits claiming its talc baby powder caused ovarian cancer, ending 10+ years of litigation.
Piper sees Intuitive Surgical staying ahead in robotic surgery, with strong growth potential despite rising competition.
Wells Fargo sees a booming psychedelic depression market, with new treatments challenging Spravato and creating big opportunities for biotech firms.
The company raised full-year guidance and remains on track for its first $100 billion revenue year.
Medicare plans drug price cuts from 2029, hitting pharma stocks, but long-term impact may be limited by legal and market protections.
The deal brings Firefly’s Firelink platform that precisely targets hard-to-treat KRAS-driven tumors while sparing healthy tissue.